Literature DB >> 14518612

Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase.

Damon Duquaine1, Glenn A Hirsch, Anjan Chakrabarti, Zhenguo Han, Chris Kehrer, Robert Brook, Joy Joseph, Anne Schott, B Kalyanaraman, Jeanette Vasquez-Vivar, Sanjay Rajagopalan.   

Abstract

Adriamycin (ADR) is a commonly used chemotherapeutic agent that is believed to exert its effects through the generation of oxygen free radicals. We hypothesized that administration of a single dose of ADR results in endothelial nitric oxide synthase (eNOS)-dependent generation of superoxide (O2*-) and acute endothelial dysfunction. A single dose of ADR (10 mg/kg i.v.) administered to rabbits resulted in rapid attenuation of agonist-dependent responses to acetylcholine and calcium ionophore (A23187). In vitro exposure of ring segments to ADR for < 30 min resulted in O2*- generation measured by electron spin resonance (ESR) with the spin trap segments 5-tert-butoxycarbonyl-5-methyl-1-pyrroline N-oxide (BMPO) that was abolished by endothelial denudation and incubation with diphenyliodonium (DPI) (10 microM) but not L-NMMA (10 microM). Brachial artery flow-mediated dilation (FMD) in patients undergoing chemotherapy with ADR was markedly attenuated after a single dose of ADR (6.5 +/- 1.0 to 2.5 +/- 1.1% (p = 0.0004, time to end of infusion 27 +/- 8 min) while endothelial-independent dilatation with nitroglycerin was unchanged (16.3 +/- 3.1 and 14.33 +/- 2.1% respectively, p = 0.36). Serum nitrite and nitrate concentrations fell from 50 +/- 6 micromol/l pre-ADR to 33 +/- 6 micromol/l post-ADR infusion (p = 0.0005) while serum concentrations of CD141 thrombomodulin and von Willebrand factor (vWF) activity remained unchanged after ADR infusion (36 +/- 13 to 52 +/- 22% ng/ml versus 3.25 +/- 0.98 to 3.01 +/- 0.91%, respectively, p = NS for pre versus post for both). Doppler indices of diastolic function (IVRT, DT and E/A ratios) were not altered in response to ADR. In conclusion, ADR administration results in rapid depletion of systemic NO* levels and attenuation of agonist-dependent responses in rabbits and flow-mediated dilation in the brachial artery of humans. ESR measurements in rabbit ring suggest an endothelial origin for radical production via flavin-containing oxido-reductases such as eNOS or NADPH cytochrome P450 reductase. These findings may have implications for cardiovascular complications noted with ADR.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14518612     DOI: 10.1191/1358863x03vm476oa

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  31 in total

Review 1.  Animal models of preeclampsia.

Authors:  Eduardo Podjarny; Gyorgy Losonczy; Chris Baylis
Journal:  Semin Nephrol       Date:  2004-11       Impact factor: 5.299

Review 2.  Biomarker Discovery in Cardio-Oncology.

Authors:  Anita Vohra; Aarti Asnani
Journal:  Curr Cardiol Rep       Date:  2018-05-25       Impact factor: 2.931

Review 3.  Doxorubicin-Induced Cardiomyopathy in Children.

Authors:  Trevi R Mancilla; Brian Iskra; Gregory J Aune
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

4.  Detrimental effects of chemotherapy on human coronary microvascular function.

Authors:  Shelby N Hader; Natalya Zinkevich; Laura E Norwood Toro; Alison J Kriegel; Amanda Kong; Julie K Freed; David D Gutterman; Andreas M Beyer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-09       Impact factor: 4.733

5.  Aortic stiffness increases upon receipt of anthracycline chemotherapy.

Authors:  Narumol Chaosuwannakit; Ralph D'Agostino; Craig A Hamilton; Kimberly S Lane; William O Ntim; Julia Lawrence; Susan A Melin; Leslie R Ellis; Frank M Torti; William C Little; W Gregory Hundley
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

6.  Anthracycline causes impaired vascular endothelial function and aortic stiffness in long term survivors of childhood cancer.

Authors:  Zoltan Jenei; Edit Bárdi; Mária Tünde Magyar; Agnes Horváth; György Paragh; Csongor Kiss
Journal:  Pathol Oncol Res       Date:  2012-12-16       Impact factor: 3.201

7.  Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q.

Authors:  Karunakaran Chandran; Deepika Aggarwal; Raymond Q Migrino; Joy Joseph; Donna McAllister; Eugene A Konorev; William E Antholine; Jacek Zielonka; Satish Srinivasan; Narayan G Avadhani; B Kalyanaraman
Journal:  Biophys J       Date:  2009-02-18       Impact factor: 4.033

Review 8.  Exercise and Aerobic Fitness to Reduce Cancer-Related Cardiovascular Toxicity.

Authors:  Umberto Campia; Ana Barac
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-07

9.  The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy.

Authors:  Hagir B Suliman; Martha Sue Carraway; Abdelwahid S Ali; Chrystal M Reynolds; Karen E Welty-Wolf; Claude A Piantadosi
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

10.  Vascular endothelial dysfunction after anthracyclines treatment in children with acute lymphoblastic leukemia.

Authors:  Woo Jung Jang; Duk Yong Choi; In-Sang Jeon
Journal:  Korean J Pediatr       Date:  2013-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.